China-based Kexing Biopharm has entered into a comprehensive strategic partnership with IQVIA, a global leader in clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.
The partnership aims to accelerate the global clinical development, regulatory approval, and commercialisation of Kexing's innovative drugs and biosimilars, with a strategic focus on Europe and other regulated international markets.
In recent years, Kexing Biopharm has taken significant steps toward internationalization by building a unique globalization platform that integrates advanced R&D capabilities with agile commercial execution.
The company has successfully facilitated the overseas market entry of several high-quality pharmaceutical products. Its in-licensed nab-paclitaxel has already achieved rapid approval and launch in several key jurisdictions. Meanwhile, the company is rapidly advancing its R&D pipeline, focusing on therapeutic areas such as antivirus, antitumor, immunosuppressant, and metabolic diseases.
This partnership leverages IQVIA's deep expertise in global clinical trial design, regulatory strategy, and data-driven insights. By combining Kexing's innovative product pipeline with IQVIA's global operational infrastructure, the two companies aim to enhance trial efficiency, and enable faster access to international markets. The collaboration is expected to significantly strengthen Kexing's global development capabilities and accelerate its transition toward becoming an international biopharmaceutical innovator.
Moving forward, Kexing will continue to deepen global collaborations to bring more high-quality Chinese pharmaceutical innovations to patients around the world.
